Intuniv patient kit draws DDMAC untitled letter

Share this article:
Intuniv patient kit draws DDMAC untitled letter
Intuniv patient kit draws DDMAC untitled letter
Patient materials for Shire's ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA's Division of Drug Marketing, Advertising and Communication.

In a June 22 untitled letter posted today, DDMAC asked Shire to stop giving out an Intuniv “patient starter kit,” including a parent guide, titration guide and ADHD support guide as well as in-office brochures. The agency said materials, which feature images of a child in a monster suit and “before and after” images, give the impression that the drug will improve individual behavioral problems in children with ADHD. That impression isn't supported by the science, said FDA.

The parent guide also suggested that the drug “improved symptoms day and night,” which the agency said “misleadingly implies that Intuniv is efficacious for a full 24-hour day.”

Some materials failed to present risk information, the agency found. Among other incidences, DDMAC noted that the front side of a branded brochure holder presented effectiveness claims for the drug but fails to present risk information – which is printed on the back of the holder, where the letter noted “it is unlikely to draw the reader's attention.”

“Moreover, the promotional materials further minimize the risks of Intuniv by failing to present risk information with a prominence and readability reasonably comparable with the presentation of claims relating to the effectiveness of the drug,” said the letter. “Specifically, the promotional materials use large and colorful headers to highlight benefits of Intuniv therapy, including a prominent and compelling image of a child in a large monster suit, while the risk information appears in small font and in single-spaced paragraph format, and in many cases only appears at the end of each piece.”
Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...